Company Name, Ticker, Suppliers, else..

Nucana Plc (NASDAQ: NCNA)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Nucana Plc's

Name: Nucana Plc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

NCNA Sales vs. its Competitors Q4 2025

Comparing the current results to its competitors, Nucana Plc reported Revenue decrease in the 4 quarter 2025 year on year by 0 %, despite the revenue increase by the most of its competitors of 3.9 %, recorded in the same quarter.

• List of NCNA Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Nucana Plc recorded a net loss, despite income increase by most of its competitors of 0 %

<< NCNA Stock Performance Comparisons

Nucana Plc's Comment on Competition and Industry Peers

The company operates in a competitive environment where other entities may discover, develop, or commercialize similar or identical products before or more successfully than it does. Its ability to compete is influenced by the adequacy of its intellectual property protection. Additionally, the company faces competition in integrating AI technologies, as competitors or third parties may implement AI into their products more rapidly and effectively. These factors may impact the company's competitive position and financial performance.

<< See the full list of NCNA competitors

*Market share is calculated based on total revenue.

NCNA's Stock Performance relative to its Competitors

Publicly Traded Peers of Nucana Plc

Spyre Therapeutics Inc
Share Performance

-8.46%

30 Days

Spyre Therapeutics Inc

Profile

Spyre Therapeutics develops long-acting antibody therapies targeting inflammatory bowel and rheumatic diseases.

More about Spyre Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ - mill.	$ - mill.	$ -178.918 mill.

Integrated Biopharma Inc
Share Performance

-4.21%

This Quarter

Integrated Biopharma Inc

Profile

Integrated Biopharma Inc's business model can be described as a vertically integrated health and wellness company focused on producing and distributing nutritional and dietary supplements.

More about Integrated Biopharma Inc's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 5.653 mill.	$ 42.568 mill.	$ -2.842 mill.

Palvella Therapeutics Inc
Share Performance

-8.24%

Over The Past 5 Days

Palvella Therapeutics Inc

Profile

Palvella Therapeutics, Inc. develops product candidates targeting rare skin diseases and vascular malformations.

More about Palvella Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 1,983.455 mill.	$ - mill.	$ -61.696 mill.

Innovation Pharmaceuticals Inc
Share Performance

0.00%

This Quarter

Innovation Pharmaceuticals Inc

Profile

Innovation Pharmaceuticals Inc operates under a business model focused on pharmaceutical research and development. They strive to innovate and discover novel drug candidates to address unmet medical needs. Through collaborations, partnerships, and internal capabilities, they aim to bring potential therapies through clinical trials and eventually to market.

More about Innovation Pharmaceuticals Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ - mill.	$ - mill.	$ -2.620 mill.

Janux Therapeutics Inc
Share Performance

-29.83%

One Year

Janux Therapeutics Inc

Profile

Janux Therapeutics Inc is a biotechnology company that focuses on developing and commercializing innovative cancer treatments. Their business model revolves around leveraging their expertise in immunotherapies and bispecific antibody platforms to create novel therapies that target tumor cells and activate the patient's immune system. By partnering with pharmaceutical companies and conducting clinical trials, they aim to bring effective and personalized cancer treatments to market.

More about Janux Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 1,025.878 mill.	$ 24.000 mill.	$ -102.592 mill.

39 more competitors available

Sources: Nucana Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Saturday, September 26, 2026 7:40 AM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Nucana Plc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.